Modeling and digitalization in pharma: Roche's approach

Dr. Patrick M. Piccione, Senior Principal Scientist at Roche, covers various aspects of modeling within their Chemistry, Manufacturing and Controls (CMC) division which focuses on the development of synthetic pharmaceutical drugs. This includes sharing insights into their organizational strategies, and showcasing the value that modeling and simulation can bring to their drug development processes via industrial examples.

The importance of embedding modeling into pharmaceutical processes

In his talk, Patrick highlights several good reasons to embed modeling into their pharmaceutical process development workflows, such as expediting time-to-market, while ensuring product quality and sustainability of their processes. Ways to achieve this in the Roche context are illustrated through applications for optimizing the planning of their experiments and scaling up their processes efficiently. To strategize a vision for digital transformation, many human factors must also be considered, such as organizational aspects and ways of working. He shares perspectives on addressing such challenges through ways of disseminating the value that modeling can deliver to various teams across their organization.